Vivo Bio Tech plans to merge with Shri Shri Resorts
The board meets on May 29 to weigh an amalgamation with the private resort operator, a move that could reshape the nano-cap research firm.
— 1 earlier story on Vivo Bio Tech Ltd. →What's new
- Vivo Bio Tech board meets May 29 to consider merging with Shri Shri Resorts Private Ltd.
- The meeting also covers audited financial results for Q4 and the full year ended March 31, 2026.
- Trading window is closed until May 31.
Why this matters
For a company valued at only ₹59 crore, absorbing a resort operator is a radical departure from its core contract research business. This proposal introduces material uncertainty regarding the firm's future asset base and earnings profile.
What we're watching
- The swap ratio or valuation terms for the proposed merger.
- The rationale for combining a research firm with a resort entity.
- Any impact on the company's balance sheet from the audited FY26 results.
The full read
Vivo Bio Tech is moving to merge with Shri Shri Resorts Private Ltd. The board meets on May 29 to review the proposal, a move that could fundamentally change the direction of the ₹59 crore contract research organization. While the meeting also includes the routine approval of audited financial results for the year ended March 31, 2026, the amalgamation is the clear outlier. Integrating a resort operator into a research firm is an unusual pivot for a company of this size. Investors now wait for the specific terms of the deal, including the valuation and the strategic logic behind the combination. The trading window remains shut until May 31. What happens next depends on whether the board can justify the shift in business profile to shareholders.
Questions answered
- What is the primary agenda for the upcoming board meeting?
- The board will consider the amalgamation of Shri Shri Resorts Private Ltd into Vivo Bio Tech and approve the audited financial results for the year ended March 31, 2026.
- When does the trading window close?
- The trading window is closed until May 31, covering the period of the board meeting.
- Why is this merger considered a significant event for the company?
- Vivo Bio Tech is a nano-cap firm with a market value of roughly ₹59 crore. An amalgamation with an external private entity could alter its business profile and asset base.
Story so far
All notes on VIVOBIOT →- 25 May 2026 · 5:39 PM IST Vivo Bio Tech plans to merge with Shri Shri Resorts
- today Vivo Bio Tech posts Q4 loss, auditor flags ₹4.19 cr in overdue dues